Drug Profile

CU 10101

Alternative Names: CU-10101

Latest Information Update: 11 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Wuhan Yingnashi Pharmaceutical
Developer Cutia Therapeutics
Class Skin disorder therapies; Small molecules
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Atopic dermatitis

Most Recent Events

31 May 2024 Pharmacodynamics data from a preclinical study in Atopic dermatitis released by Cutia Therapeutics
30 May 2024 Center for Drug Evaluation of the National Medical Products Administration approves the IND application of CU 10101 for Atopic dermatitis
27 Mar 2024 Center for Drug Evaluation of the National Medical Products Administration accepts the IND application of CU 10101 for atopic dermatitis

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com